2026 Annual Meeting | C51 - Alzheimer's Disease

Date Sunday 04/19/26

Time 07:00 AM - 09:00 AM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Eric M. McDade, DO

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives At the end of the course participants should identify the current state of blood-based biomarkers for the diagnosis of Alzheimer’s disease and the appraise the potential utility of these biomarkers for monitoring treatment with amyloid-beta immunotherapies. Additionally, participants will review the data on the real-world application of amyloid-beta immunotherapies including specific cases that illustrate safety, monitoring and clinical outcomes ; lastly, participants will examine the reasons for, evaluation of and treatment approach to sleep disorders in Alzheimer and related dementias- a source of significant burden to patients and caregivers.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Advanced

Recommended Audience Fellow, Resident, General Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic

Event Timeline
07:00 AM - 07:10 AM CDT	Introduction	Alzheimer Disease Updates on Diagnosis and Treatment Eric M. McDade, DO
07:10 AM - 07:40 AM CDT	Speaker	Fluid Biomarkers in the Diagnosis and Treatment of Alzheimer’s Disease Suzanne E. Schindler, MD, PhD
07:40 AM - 08:10 AM CDT	Speaker	Real World Experience with Anti-amyloid Immunotherapy for the Treatment of Alzheimer's Disease Eric M. McDade, DO
08:10 AM - 08:40 AM CDT	Speaker	Causes and Treatment of Sleep Disorders in Alzheimer's Disease Jennifer R. Molano, MD, FAAN
08:40 AM - 09:00 AM CDT	Q&A	Questions and Answers Eric M. McDade, DO

Faculty Disclosures
Eric M. McDade, DO	Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. McDade has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alzamend. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche-Genentech. The institution of Dr. McDade has received research support from NIA. The institution of Dr. McDade has received research support from Eli Lilly. The institution of Dr. McDade has received research support from Hoffman-La Roche. The institution of Dr. McDade has received research support from Eisai. The institution of Dr. McDade has received research support from Eisai. Dr. McDade has received intellectual property interests from a discovery or technology relating to health care. Dr. McDade has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with Fondation Alzheimer.
Suzanne E. Schindler, MD, PhD	Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Schindler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. The institution of Dr. Schindler has received research support from National Institute on Aging. Dr. Schindler has received personal compensation in the range of $0-$499 for serving as a Member of the Biospecimen Review Committee with National Centralized Repository for Alzheimer Disease. Dr. Schindler has a non-compensated relationship as a Board Member with Greater Missouri Alzheimer's Association that is relevant to AAN interests or activities.
Jennifer R. Molano, MD, FAAN	Dr. Molano has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society . The institution of Dr. Molano has received research support from National Institutes of Health.

��ɫ��

��ɫ��